^
    Back
    Association details:
    Biomarker:KRAS mutation + STK11 mutation + AXL expression
    Cancer:Lung Adenocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    bemcentinib (BGB324) (AXL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cell Reports Medicine
    Title:

    AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

    Published date:
    03/15/2022
    Excerpt:
    ...we studied two human LUAD KL-mutated cell lines, A549 and H2122, in a humanized NSG-SGM3 mouse model. Although these cell lines harbor KRAS and STK11/LKB1 mutations...A549 express AXL while H2122 has limited AXL expression...BGB324 sensitized A549 and H2122 tumors in humanized mice to pembrolizumab...
    DOI:
    https://doi.org/10.1016/j.xcrm.2022.100554